# Proteomics Shared Resource

> **NIH NIH P30** · MAYO CLINIC ROCHESTER · 2021 · $160,901

## Abstract

PROTEOMICS SHARED RESOURCE PROJECT SUMMARY 
The Mayo Clinic Cancer Center (MCCC) Proteomics Shared Resource (PRO) is a full-service facility that 
provides essential services in peptide synthesis, protein analysis, protein and peptide separation, mass 
spectrometry, proteomics applications, and expertise in project planning, sample preparation, data acquisition 
and analysis. The PRO occupies a total of 4920 sq. ft. on the 3rd floor of the Medical Sciences Building, and is 
located at the Mayo Clinic in Rochester (MCR) site. The 8 PRO staff members have broad knowledge and 
expertise in the services provided. The PRO Director, Dr. Daniel J. McCormick, provides visionary direction, 
planning, recruitment, and executive decisions regarding all operations, staffing, and services. Working with 
institutional committees and centers for over 33 years, Dr. McCormick has been able to provide scientific 
direction and support for high-end core instrumentation, and new technologies in protein chemistry, proteomics 
and mass spectrometry (MS) to support Programs of MCCC members in cancer research. In the previous 
funded period, 6 new service-lines (e.g., label-free differential proteomics, expanded phosphoproteomics by 
SCX fractionation and TiO2 enrichment, proteomics analysis of FFPE and Frozen tissue, high/low pH LC 
sample fractionation, de novo MS/MS protein sequencing, and MS analysis of complex glycans) were 
developed to support the protein analysis needs of MCCC members. Scientific achievements include: 
identification of key proteins that interact with TAT2 protein in myeloid cancers; development of agents that 
inhibit TGFß action (via SMAD signaling) and prevent glioblastoma migration in PDX cell lines; identification of 
key phosphoproteins (e.g., CXCR4) downregulated in Alisertib-treated human breast adenocarcinoma; 
mapping sites of phosphorylation in SOX2, a transcriptional activator of “stemness” phenotype in lung 
squamous cell carcinoma; synthesis of oncoprotein antigens for in vitro activation of naïve T-cells in adoptive 
T-cell therapies to treat cancer (e.g., pancreatic); and differential analysis of proteins activated by SPINK1 in 
ovarian cancer proliferation. PRO utilization by MCCC members has been strong with a total average usage of 
51% by 99 members (72 peer-reviewed) in the current funded period (2013-2017). The PRO is used by MCCC 
members from all 3 sites, including 12 members from Mayo Clinic in Florida and 5 members from Mayo Clinic 
in Arizona. The PRO provides free consultation, project design, and data interpretation to MCCC members, 
and provides its services on fee-for-service basis; standardized forms for project and service requests are on 
the resources' internal web site. Comparison of rates for many services of the PRO to external cores and 
vendors, was completed in 2017 and indicated that core rates were highly competitive. Future directions of the 
PRO include: deep sequencing proteomics with advanced MS ins...

## Key facts

- **NIH application ID:** 10113579
- **Project number:** 5P30CA015083-47
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** AKHILESH PANDEY
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $160,901
- **Award type:** 5
- **Project period:** 2020-03-01 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10113579

## Citation

> US National Institutes of Health, RePORTER application 10113579, Proteomics Shared Resource (5P30CA015083-47). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10113579. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*